Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MLYS Mineralys Therapeutics	$13.94 +2.8%	$13.00	$8.24 ▼ $18.38	$904.37M	-0.39	430,213 shs	458,472 shs
NTLA Intellia Therapeutics	$8.20 -3.3%	$8.59	$5.90 ▼ $28.18	$848.84M	2.23	2.40 million shs	2.85 million shs
PLX Protalix BioTherapeutics	$2.96 +3.9%	$2.46	$0.82 ▼ $3.04	$230.98M	0.46	468,609 shs	674,530 shs
SYRE Spyre Therapeutics	$15.02 +2.4%	$16.27	$10.91 ▼ $40.49	$905.35M	3.05	600,077 shs	355,834 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MLYS Mineralys Therapeutics	+1.65%	+2.42%	-7.50%	+37.53%	+14.24%
NTLA Intellia Therapeutics	+2.05%	+7.07%	+5.08%	-15.28%	-59.15%
PLX Protalix BioTherapeutics	0.00%	+11.76%	+10.47%	+23.38%	+147.83%
SYRE Spyre Therapeutics	+3.82%	+8.11%	-18.23%	-32.68%	-56.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MLYS Mineralys Therapeutics	2.4029 of 5 stars	3.5	1.0	0.0	1.9	5.0	0.0
NTLA Intellia Therapeutics	4.6144 of 5 stars	4.3	1.0	4.7	3.3	2.5	1.3
PLX Protalix BioTherapeutics	2.6954 of 5 stars	3.5	0.0	0.0	3.2	0.0	1.9
SYRE Spyre Therapeutics	1.9262 of 5 stars	3.6	0.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MLYS Mineralys Therapeutics	3.00	Buy	$33.00	136.73% Upside
NTLA Intellia Therapeutics	2.65	Moderate Buy	$36.68	347.37% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	406.76% Upside
SYRE Spyre Therapeutics	3.20	Buy	$49.57	230.04% Upside

Current Analyst Ratings Breakdown

Latest PLX, SYRE, MLYS, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/21/2025	NTLA Intellia Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$21.00
4/8/2025	SYRE Spyre Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/8/2025	SYRE Spyre Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
4/2/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$30.00 ➝ $42.00
3/18/2025	SYRE Spyre Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
3/10/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/5/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
3/4/2025	NTLA Intellia Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$90.00 ➝ $50.00
2/28/2025	NTLA Intellia Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $26.00
2/28/2025	NTLA Intellia Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$12.00 ➝ $14.00
2/28/2025	NTLA Intellia Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$60.00 ➝ $50.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
NTLA Intellia Therapeutics	$57.88M	14.67	N/A	N/A	$11.73 per share	0.70
PLX Protalix BioTherapeutics	$53.40M	4.33	$0.17 per share	17.80	$0.47 per share	6.30
SYRE Spyre Therapeutics	$890K	1,017.24	N/A	N/A	($0.22) per share	-68.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MLYS Mineralys Therapeutics	-$177.81M	-$3.64	N/A	N/A	N/A	N/A	-67.97%	-62.40%	5/8/2025 (Estimated)
NTLA Intellia Therapeutics	-$481.19M	-$5.25	N/A	N/A	N/A	N/A	-49.34%	-40.27%	5/8/2025 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.03	N/A	9.55	N/A	-21.03%	-30.89%	-11.74%	N/A
SYRE Spyre Therapeutics	-$338.79M	-$4.23	N/A	N/A	N/A	N/A	-210.01%	-44.40%	5/8/2025 (Estimated)

Latest PLX, SYRE, MLYS, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	N/A	N/A	N/A	$11.39 million	N/A
5/8/2025	Q1 2025	SYRE Spyre Therapeutics	-$0.74	N/A	N/A	N/A	N/A	N/A
2/27/2025	Q4 2024	SYRE Spyre Therapeutics	-$0.89	-$0.81	+$0.08	-$0.81	$2.10 million	N/A
2/12/2025	Q4 2024	MLYS Mineralys Therapeutics	-$1.00	-$0.98	+$0.02	-$0.98	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MLYS Mineralys Therapeutics	N/A	14.02	14.02
NTLA Intellia Therapeutics	N/A	6.73	6.73
PLX Protalix BioTherapeutics	N/A	1.98	1.27
SYRE Spyre Therapeutics	N/A	7.32	7.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MLYS Mineralys Therapeutics	84.46%
NTLA Intellia Therapeutics	88.77%
PLX Protalix BioTherapeutics	16.53%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
MLYS Mineralys Therapeutics	33.24%
NTLA Intellia Therapeutics	3.20%
PLX Protalix BioTherapeutics	6.30%
SYRE Spyre Therapeutics	6.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MLYS Mineralys Therapeutics	28	64.88 million	33.27 million	Optionable
NTLA Intellia Therapeutics	600	103.52 million	98.59 million	Optionable
PLX Protalix BioTherapeutics	200	78.03 million	69.00 million	Optionable
SYRE Spyre Therapeutics	100	60.28 million	48.24 million	Optionable

PLX, SYRE, MLYS, and NTLA Headlines

Recent News About These Companies

Adage Capital Partners GP L.L.C. Lowers Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 28 at 5:37 AM | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Trading Down 3.6% - Here's Why

April 24, 2025 | marketbeat.com

Capital World Investors Invests $8.81 Million in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 24, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Trading Up 6.3% - Still a Buy?

April 23, 2025 | marketbeat.com

B Group Inc. Buys Shares of 50,000 Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 23, 2025 | marketbeat.com

Geode Capital Management LLC Buys 75,081 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 21, 2025 | marketbeat.com

Affinity Asset Advisors LLC Purchases 325,908 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 17, 2025 | marketbeat.com

Fmr LLC Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 15, 2025 | marketbeat.com

Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Up 6.55%

April 14, 2025 | aaii.com

F M Investments LLC Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 14, 2025 | marketbeat.com

Vanguard Group Inc. Buys 330,553 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 13, 2025 | marketbeat.com

What is Leerink Partnrs' Estimate for SYRE Q1 Earnings?

April 12, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Upgraded to "Strong-Buy" at Leerink Partnrs

April 11, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Now Covered by Leerink Partners

April 10, 2025 | marketbeat.com

Spyre Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:SYRE | Benzinga

April 9, 2025 | benzinga.com

Spyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year Low - Here's What Happened

April 9, 2025 | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of "Buy" from Analysts

April 9, 2025 | marketbeat.com

Leerink Partners Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform Recommendation

April 8, 2025 | msn.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Wellington Management Group LLP

April 8, 2025 | marketbeat.com

Schroder Investment Management Group Takes $2.56 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

April 8, 2025 | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Holdings Lowered by Cinctive Capital Management LP

April 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX, SYRE, MLYS, and NTLA Company Descriptions

Mineralys Therapeutics NASDAQ:MLYS

$13.94 +0.38 (+2.80%)

Closing price 04:00 PM Eastern

Extended Trading

$13.92 -0.01 (-0.11%)

As of 04:05 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Intellia Therapeutics NASDAQ:NTLA

$8.20 -0.28 (-3.30%)

Closing price 04:00 PM Eastern

Extended Trading

$8.27 +0.07 (+0.85%)

As of 07:58 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Protalix BioTherapeutics NYSE:PLX

$2.96 +0.11 (+3.86%)

Closing price 04:00 PM Eastern

Extended Trading

$2.95 -0.01 (-0.34%)

As of 07:15 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Spyre Therapeutics NASDAQ:SYRE

$15.02 +0.35 (+2.39%)

Closing price 04:00 PM Eastern

Extended Trading

$14.98 -0.04 (-0.30%)

As of 04:27 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time